MSFT 437.49 1.4587% AAPL 242.99 0.1401% NVDA 145.11 3.4579% GOOGL 174.36 1.7626% GOOG 176.05 1.7512% AMZN 218.21 2.2348% META 613.54 -0.0179% AVGO 170.365 1.3173% TSLA 357.75 1.8013% TSM 200.69 0.905% LLY 833.585 2.4904% V 310.57 -0.7795% JPM 243.555 -0.5167% UNH 610.73 0.9087% NVO 109.26 0.0549% WMT 94.295 0.8395% LVMUY 127.2 -0.9269% XOM 114.29 -2.8724% LVMHF 638.8 -0.6084% MA 521.685 -0.8543%
Last update at 2024-12-04T20:55:00Z
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Thu 21 Nov 24, 07:00 AM5 Healthcare Stocks to Buy in a Beaten-Up Sector
Thu 14 Nov 24, 06:53 PMHims & Hers will start selling a generic weight loss drug
Tue 05 Nov 24, 03:50 PMKnockoff weight loss drugs are having a moment. Eli Lilly isn't worried
Wed 30 Oct 24, 06:32 PMA non-opioid pain med, a COVID-flu shot combo, and more: 7 drug launches to watch in 2025
Fri 25 Oct 24, 09:00 AMOzempic May Reduce the Risk of Alzheimer’s. That’s Huge for Novo Nordisk.
Thu 24 Oct 24, 02:37 PMI'm a pharmacist. Knockoff Ozempic and other weight loss products have serious hidden risks
Mon 21 Oct 24, 01:55 PMMarket Chatter: Eli Lilly Files Suits Against Companies Selling Weight-Loss Drug
Mon 21 Oct 24, 12:12 PM1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now
Sat 19 Oct 24, 10:10 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 6806.40M | 6155.50M | 7229.90M | 5265.90M | 3680.10M |
Minority interest | - | - | 183.60M | 92.20M | 1080.40M |
Net income | 6244.80M | 5581.70M | 6193.70M | 4637.90M | 3232.00M |
Selling general administrative | 6440.40M | 6431.60M | 6121.20M | 6213.80M | 5975.10M |
Selling and marketing expenses | - | - | - | 6213.80M | 5975.10M |
Gross profit | 21911.60M | 21005.60M | 19056.50M | 17598.30M | 16811.60M |
Reconciled depreciation | 1522.50M | 1547.60M | 1323.90M | 1232.60M | 1609.00M |
Ebit | 7127.30M | 6357.10M | 6058.00M | 4974.30M | 8036.10M |
Ebitda | 9433.50M | 8739.10M | 7641.20M | 6604.70M | 9645.10M |
Depreciation and amortization | 2306.20M | 2382.00M | 1583.20M | 1630.40M | 1609.00M |
Non operating income net other | -320.90000M | - | - | 291.60M | 74.80M |
Operating income | 7127.30M | 6357.10M | 6058.00M | 4974.30M | 6186.80M |
Other operating expenses | 20261.00M | 20770.30M | 17690.20M | 16530.00M | 15708.00M |
Interest expense | 331.60M | 339.80M | 359.60M | 400.60M | 272.10M |
Tax provision | 561.60M | 573.80M | 1036.20M | 628.00M | 563.70M |
Interest income | 268.80M | 314.40M | 326.60M | 80.40M | 161.30M |
Net interest income | -268.80000M | -314.40000M | -326.60000M | -320.20000M | -110.80000M |
Extraordinary items | - | 0.00000M | 0.00000M | 3680.50M | -93.90000M |
Non recurring | 244.60M | - | - | 815.20M | 2465.90M |
Other items | - | - | - | - | - |
Income tax expense | 561.60M | 573.80M | 1036.20M | 628.00M | 529.50M |
Total revenue | 28541.40M | 28318.40M | 24539.80M | 22319.50M | 21493.30M |
Total operating expenses | 13631.20M | 13457.50M | 12206.90M | 11808.80M | 11026.30M |
Cost of revenue | 6629.80M | 7312.80M | 5483.30M | 4721.20M | 4681.70M |
Total other income expense net | -320.90000M | -201.60000M | 1171.90M | 291.60M | -2105.20000M |
Discontinued operations | - | - | - | 3680.50M | 81.40M |
Net income from continuing ops | 6244.80M | 5581.70M | 6193.70M | 4637.90M | 3232.00M |
Net income applicable to common shares | 6244.80M | 5581.70M | 6193.70M | 8318.40M | 3232.00M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 49489.80M | 48806.00M | 46633.10M | 39286.10M | 43908.40M |
Intangible assets | 7206.60M | 7691.90M | 7450.00M | 6618.00M | 1068.00M |
Earning assets | - | - | - | - | - |
Other current assets | 2954.10M | 2530.60M | 2871.50M | 2538.90M | 2146.50M |
Total liab | 38714.40M | 39651.20M | 40807.90M | 36587.00M | 32999.30M |
Total stockholder equity | 10649.80M | 8979.20M | 5641.60M | 2606.90M | 9828.70M |